Table 1.
Baseline demographic and clinical characteristics of included patients diagnosed with and without bone metastasis.
| Variables | Level | Bone metastasis | P-value | |
|---|---|---|---|---|
|
Yes (N = 559) |
No (N = 22,233) |
|||
| Age [median (IQR)] |
56.00 [47.00, 65.00] | 49.00 [39.00, 61.00] | <0.001 | |
| Race (%) | Black | 97 (17.4) | 3,063 (13.8) | 0.006 |
| Other | 52 (9.3) | 2,355 (10.6) | ||
| Unknown | 0 (0.0) | 253 (1.1) | ||
| White | 410 (73.3) | 16,562 (74.5) | ||
| Year (%) | 2010 | 60 (10.7) | 3,167 (14.2) | 0.004 |
| 2011 | 60 (10.7) | 3,137 (14.1) | ||
| 2012 | 74 (13.2) | 3,174 (14.3) | ||
| 2013 | 82 (14.7) | 3,001 (13.5) | ||
| 2014 | 88 (15.7) | 3,226 (14.5) | ||
| 2015 | 108 (19.3) | 3,252 (14.6) | ||
| 2016 | 87 (15.6) | 3,276 (14.7) | ||
| Primary_site* (%) | Cervix uteri | 495 (88.6) | 17,208 (77.4) | <0.001 |
| Endocervix | 56 (10.0) | 4,267 (19.2) | ||
| Exocervix | 2 (0.4) | 410 (1.8) | ||
| OLC | 6 (1.1) | 348 (1.6) | ||
| Grade (%) | Grade I | 10 (1.8) | 2,527 (11.4) | <0.001 |
| Grade II | 89 (15.9) | 6,946 (31.2) | ||
| Grade III | 229 (41.0) | 6,202 (27.9) | ||
| Grade IV | 27 (4.8) | 516 (2.3) | ||
| Unknown | 204 (36.5) | 6,042 (27.2) | ||
| Pathology (%) | ADC | 78 (14.0) | 4,202 (18.9) | <0.001 |
| SCC | 314 (56.2) | 14,253 (64.1) | ||
| Others | 167 (29.9) | 3,778 (17.0) | ||
| SEER_historicϵ (%) | Distant | 472 (84.4) | 2,363 (10.6) | <0.001 |
| Localized | 0 (0.0) | 8,787 (39.5) | ||
| Regional | 0 (0.0) | 7,427 (33.4) | ||
| Unknown | 87 (15.6) | 3,656 (16.4) | ||
T_stage
(%)
|
T0 | 2 (0.4) | 11 (0.0) | <0.001 |
| T1 | 62 (11.1) | 10,401 (46.8) | ||
| T2 | 83 (14.8) | 4,163 (18.7) | ||
| T3 | 186 (33.3) | 2,865 (12.9) | ||
| T4 | 57 (10.2) | 676 (3.0) | ||
| TX | 78 (14.0) | 691 (3.1) | ||
| Unknown | 91 (16.3) | 3,426 (15.4) | ||
|
N_stage
(%)
|
N0 | 119 (21.3) | 13,562 (61.0) | <0.001 |
| N1 | 291 (52.1) | 4,552 (20.5) | ||
| NX | 58 (10.4) | 693 (3.1) | ||
| Unknown | 91 (16.3) | 3,426 (15.4) | ||
|
M_stage
(%)
|
M0 | 0 (0.0) | 16,641 (74.8) | <0.001 |
| M1 | 468 (83.7) | 2,166 (9.7) | ||
| Unknown | 91 (16.3) | 3,426 (15.4) | ||
| Lymph_biopsy (%) | >4 | 8 (1.4) | 7,258 (32.6) | <0.001 |
| ≤ 3 | 7 (1.3) | 458 (2.1) | ||
| Unknown | 544 (97.3) | 14,517 (65.3) | ||
| Surgery (%) | No | 520 (93.0) | 9,654 (43.4) | <0.001 |
| Unknown | 0 (0.0) | 35 (0.2) | ||
| Yes | 39 (7.0) | 12,544 (56.4) | ||
|
Regional_nodes_
examined (%) |
Negative | 512 (91.6) | 13,787 (62.0) | <0.001 |
| Positive | 28 (5.0) | 8,138 (36.6) | ||
| Unknown | 19 (3.4) | 308 (1.4) | ||
| Bone_metastasis (%) | No | 0 (0.0) | 22,233 (100.0) | <0.001 |
| Yes | 559 (100.0) | 0 (0.0) | ||
| Brain_metastasis (%) | No | 504 (90.2) | 22,171 (99.7) | <0.001 |
| Unknown | 20 (3.6) | 12 (0.1) | ||
| Yes | 35 (6.3) | 50 (0.2) | ||
| Liver_metastasis (%) | No | 387 (69.2) | 21,874 (98.4) | <0.001 |
| Unknown | 14 (2.5) | 25 (0.1) | ||
| Yes | 158 (28.3) | 334 (1.5) | ||
| Lung_metastasis (%) | No | 314 (56.2) | 21,435 (96.4) | <0.001 |
| Unknown | 22 (3.9) | 48 (0.2) | ||
| Yes | 223 (39.9) | 750 (3.4) | ||
|
Distant_Lymph_
metastasis (%) |
No | 44 (7.9) | 3,033 (13.6) | <0.001 |
| Unknown | 474 (84.8) | 18,969 (85.3) | ||
| Yes | 41 (7.3) | 231 (1.0) | ||
| CS_tumor_size (%), cm | <5 | 251 (44.9) | 13,007 (58.5) | <0.001 |
| ≥5 | 1 (0.2) | 454 (2.0) | ||
| Unknown | 307 (54.9) | 8,772 (39.5) | ||
| Insurance (%) | Any Medicaid | 183 (32.7) | 6,704 (30.2) | 0.306 |
| Insured | 323 (57.8) | 13,484 (60.6) | ||
| Uninsured | 40 (7.2) | 1,376 (6.2) | ||
| Unknown | 13 (2.3) | 669 (3.0) | ||
| Marital_status (%) | Married | 360 (64.4) | 14,009 (63.0) | 0.139 |
| Unknown | 24 (4.3) | 1,414 (6.4) | ||
| Unmarried | 175 (31.3) | 6,810 (30.6) | ||
| Survival status (%) | Alive | 117 (20.9) | 16,507 (74.2) | <0.001 |
| Dead | 442 (79.1) | 5,726 (25.8) | ||
| Survival time [median (IQR)] | 5.00 [2.00, 12.00] | 23.00 [9.00, 47.00] | <0.001 | |
*
According to the primary site labeled. According to the American Joint Committee on Cancer (AJCC), 6th. € According to the SEER historic stage (1973–2015). IQR, Interquartile range; OLC, Overlapping lesion of cervix uteri; ADC, Adenocarcinoma; SCC, Squamous cell carcinoma.